{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:24Z","timestamp":1786982844026,"version":"build-2736575974"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40620-020-00721-4","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T23:02:45Z","timestamp":1584658965000},"page":"221-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New drugs for the treatment of Anderson\u2013Fabry disease"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-8447","authenticated-orcid":false,"given":"Sandro","family":"Feriozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"721_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"PD Germain","year":"2010","unstructured":"Germain PD (2010) Fabry disease. Orphan J Rare Dis 5:30","journal-title":"Orphan J Rare Dis"},{"key":"721_CR2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D et al (2017) Characterization of classical and non-classical Fabry disease. J Am Soc Nephrol 28:1631\u20131641","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"721_CR3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A et al (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89(1):44\u201354","journal-title":"Clin Genet"},{"issue":"4","key":"721_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","volume":"47","author":"GE Linthorst","year":"2010","unstructured":"Linthorst GE, Bouwman MG, Wijburg FA et al (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47(4):217\u2013222","journal-title":"J Med Genet"},{"issue":"5","key":"721_CR5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52(5):353\u2013358","journal-title":"J Med Genet"},{"key":"721_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymgmr.2017.10.008","volume":"14","author":"M Beck","year":"2017","unstructured":"Beck M, Hughes D, Kampmann C et al (2017) Long-term outcomes with agalsidasealfa enzyme replacement therapy; Analysis using deconstructed composite events. Mol Genet Metab Rep 14:31\u201335","journal-title":"Mol Genet Metab Rep"},{"issue":"11","key":"721_CR7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, Wets M, Pintos-Morell G (2010) Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature. Genet Med 12(11):668\u2013679","journal-title":"Genet Med"},{"key":"721_CR8","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E (2018) Effects of enzyme replacement therapy and antidrug antibodies inn patients with Fabry disease. J Am soc Nephrol 29:2265\u20132278","journal-title":"J Am soc Nephrol"},{"key":"721_CR9","unstructured":"Medicine Agency Migalastat ( Galafold) :EU Summary of product characteristics 2018. https :\/\/www.ema.europ a.eu\/"},{"issue":"1","key":"721_CR10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","volume":"19","author":"GH Yam","year":"2005","unstructured":"Yam GH, Zuber C, Roth J et al (2005) A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding. Faseb J 19(1):12\u201318","journal-title":"Faseb J"},{"issue":"4","key":"721_CR11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X et al (2017) The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med 19(4):430\u2013438","journal-title":"Genet Med"},{"key":"721_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12167","author":"A Novak","year":"2019","unstructured":"Novak A, Huynh-Do U, Krayenbuehl P et al (2019) Fabry disease genotype, phenotype and Migalastat amenability: insights from a national cohort. J Inherit Metab Dis. https:\/\/doi.org\/10.1002\/jimd.12167","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"721_CR13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ (2019) Migalastat A review in Fabry disease. Drugs 79(5):543\u2013554","journal-title":"Drugs"},{"key":"721_CR14","unstructured":"Amicus Therapeutics. Galafold\u2122 (migalastat) capsules: NDA approval letter. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/20862 3Orig1s000ltr.pdf"},{"issue":"6","key":"721_CR15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR et al (2016) Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med 375(6):545\u2013555","journal-title":"N Engl J Med"},{"issue":"4","key":"721_CR16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K et al (2017) Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54(4):288\u2013296","journal-title":"J Med Genet"},{"key":"721_CR17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmud CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Inter Med 150:604\u2013612","journal-title":"Ann Inter Med"},{"issue":"5","key":"721_CR18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","volume":"105","author":"J Muntze","year":"2019","unstructured":"Muntze J, Gensler D, Maniuc O et al (2019) Oral chaperone therapy: Migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther 105(5):1224\u20131233","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"721_CR19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","volume":"56","author":"M Lenders","year":"2019","unstructured":"Lenders M, Stappers F, Niemietz C et al (2019) Mutation-specific Fabry disease patient-derived cel model to evaluate the amenability to chaperone therapy. J Med Genet 56(8):548\u2013556","journal-title":"J Med Genet"},{"issue":"9","key":"721_CR20","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","volume":"21","author":"DP Germain","year":"2019","unstructured":"Germain DP, Nicholls K, Giugliani R et al (2019) Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants : data from the phase 3 randomised, multicentre, double-blind clinical trial and extension study. Genet Med 21(9):1987\u20131997","journal-title":"Genet Med"},{"issue":"21","key":"721_CR21","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"F Veronese","year":"2005","unstructured":"Veronese F, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10(21):1451\u20131458","journal-title":"Drug Discov Today"},{"issue":"8","key":"721_CR22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/pbi.12428","volume":"13","author":"Y Tekoah","year":"2015","unstructured":"Tekoah Y, Shulman A, Kizhner T et al (2015) Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience. Plant Biotechnol J 13(8):1199\u20131208","journal-title":"Plant Biotechnol J"},{"key":"721_CR23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulav Y, Hainrichson M et al (2015) Characterizarion of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Faby disease. Mol Genet Met 114:259\u2013267","journal-title":"Mol Genet Met"},{"issue":"3","key":"721_CR24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Shiffmann","year":"2019","unstructured":"Shiffmann R, Goker-Alpan O et al (2019) Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease provides sustained plasma concentrations and favourable pharmacodynamics: a 1 year Phase 1\/2 clinical trial. J Inherit Metab Dis 42(3):534\u2013544","journal-title":"J Inherit Metab Dis"},{"key":"721_CR25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1021\/acs.bioconjchem.8b00133","volume":"29","author":"I Ruderfer","year":"2018","unstructured":"Ruderfer I, Shulman A, Kizhner A, Azulav Y, Natal Y, Tokoa Y, Shaaltiel Y (2018) Development and analytical characterization of Pegunigalsidase alfa, a chemical crosslinked plant recombinant human \u03b1-galactosidase A for treatment of Fabry disease. Bioconjug Chem 29:1640\u20131648","journal-title":"Bioconjug Chem"},{"key":"721_CR26","first-page":"S15","volume":"123","author":"D Hughes","year":"2018","unstructured":"Hughes D, Giraldo P, Holida M et al (2018) Pegunigalsidas alfa a novel PEGylated ERT for Fabry disease: two-year safety and efficacy follow-up. Mol Genet Metab 123:S15\u2013S153","journal-title":"Mol Genet Metab"},{"key":"721_CR27","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.ymgme.2018.12.389","volume":"126","author":"D Warnock","year":"2018","unstructured":"Warnock D, Eric W, Shiffmann R et al (2018) Analysis of the baseline characteristics of Fabry disease patients screened for Pegunigalsidase alfa phase III BALANCE study. Mol Genet Metab 126:S150\u2013S152","journal-title":"Mol Genet Metab"},{"key":"721_CR28","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.ymgme.2018.12.176","volume":"126","author":"MD Holida","year":"2019","unstructured":"Holida MD, Bernat J, Longo N et al (2019) Once every 4 weeks-2mg\/kgb of Pegunigalsidase alfa for treating Fabry disease Preliminary results of phase 3. Mol Genet Metab 126:S17\u2013S156","journal-title":"Mol Genet Metab"},{"key":"721_CR29","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.ymgme.2018.12.234","volume":"126","author":"A Linhart","year":"2019","unstructured":"Linhart A, Nicholls M, West M et al (2019) Pegunigalsidase alfa for treatment of fabry disease: preliminary results from a phase III open label; switch over study from agalsidase alfa. Mol Genet Metab 126:S17\u2013S156","journal-title":"Mol Genet Metab"},{"key":"721_CR30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1467-7652.2004.00100.x","volume":"2","author":"A Koiprova","year":"2002","unstructured":"Koiprova A, Stemmer C, Altmann F et al (2002) Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol J 2:517\u2013523","journal-title":"Plant Biotechnol J"},{"key":"721_CR31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","volume":"39","author":"J-S Shen","year":"2016","unstructured":"Shen J-S, Busch A, Day TS et al (2016) Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis 39:293\u2013303","journal-title":"J Inherit Metab Dis"},{"key":"721_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jimd.12052","volume":"42","author":"J Hennermann","year":"2019","unstructured":"Hennermann J, Arash-Kaps L, Feke G et al (2019) Pharmacokinetics, pharmacodynamics and safety of moss-a Galactosidase A in patients with Fabry disease. J Inherit Metab Dis 42:1\u20137","journal-title":"J Inherit Metab Dis"},{"key":"721_CR33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","volume":"97","author":"R Shiffmann","year":"2000","unstructured":"Shiffmann R, Murray GJ, Treco D et al (2000) Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci 97:365\u2013370","journal-title":"Proc Natl Acad Sci"},{"key":"721_CR34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Guerard","year":"2018","unstructured":"Guerard N, Oder D, Nordbeck P et al (2018) Lucerastat, an iminosugar for substrate reduction: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther 103:703\u2013711","journal-title":"Clin Pharmacol Ther"},{"key":"721_CR35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","volume":"97","author":"FM Platt","year":"2008","unstructured":"Platt FM, Jayakumar M (2008) Substrate reduction therapy. Acta Pediatr 97:88\u201393","journal-title":"Acta Pediatr"},{"key":"721_CR36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM et al (2015) Efficacy of enzyme substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med 21:389\u2013399","journal-title":"Mol Med"},{"key":"721_CR37","first-page":"5033","volume":"5","author":"R Marshall","year":"2010","unstructured":"Marshall R et al (2010) Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. Plos One 5:5033","journal-title":"Plos One"},{"issue":"6","key":"721_CR38","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.neuint.2007.12.001","volume":"52","author":"RC Baek","year":"2008","unstructured":"Baek RC, Kasperzyk JL, Platt FM et al (2008) Butyldeoxgalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52(6):1125\u20131133","journal-title":"Neurochem Int"},{"key":"721_CR39","unstructured":"Weford RWD et al (2017) Lucerastat, an iminosugar substrate reduction therapy for Fabry disease: preclinical evidence. World LDN 2017 Abs 360"},{"key":"721_CR40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jcph.944","volume":"57","author":"N Guerard","year":"2017","unstructured":"Guerard N, Zwingelstein C, Dingemanse J (2017) Lucerastat, an iminosugar for substrate reduction therapy: tolerability and safety in subjects with mild, moderate and severe renal impairment. J Clin Pharmacol 57:1425\u20131431","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"721_CR41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Guerard","year":"2018","unstructured":"Guerard N, Oder D, Norbeck P et al (2018) Lucerastat an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Phatmacol Ther 103(4):703\u2013711","journal-title":"Clin Phatmacol Ther"},{"key":"721_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.05.001","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C et al (2017) Favourable effect of early versus late enzyme replacement therapy on plasma globotriaosylsphingosine in men with classical Fabry disease. Mol Genet Metab. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.001","journal-title":"Mol Genet Metab"},{"key":"721_CR43","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1566523218666180404161315","volume":"18","author":"I Simonetta","year":"2018","unstructured":"Simonetta I, Tuttolomondo A, Di Chiara T et al (2018) Genetics and gene therapy of Anderson-Fabry disease. Curr Gene Ther 18:96\u2013106","journal-title":"Curr Gene Ther"},{"key":"721_CR44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14712598.2019.1607837","volume":"19","author":"S Murtaza","year":"2019","unstructured":"Murtaza S, Nagree MS, Scalia S et al (2019) An update on gene therapy for lysosomal storage disorders. Exp Opin Biol Ther 19:655\u2013670","journal-title":"Exp Opin Biol Ther"},{"key":"721_CR45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","volume":"27","author":"APR de Garibay","year":"2013","unstructured":"de Garibay APR, Solinis MA, Rodriguez-Gascon A (2013) Gene therapy for Fabry disease: a review of the Literature. BioDrugs 27:237\u2013246","journal-title":"BioDrugs"},{"issue":"S17","key":"721_CR46","first-page":"S156","volume":"126","author":"MS Nagree","year":"2019","unstructured":"Nagree MS, Faber ML, Tate E et al (2019) In vivo enrichment of traduced cells to enhance gene therapy. MGM 126(S17):S156","journal-title":"MGM"},{"key":"721_CR47","first-page":"S17","volume":"126","author":"J Jeyakumar","year":"2019","unstructured":"Jeyakumar J, Kia A, McIntosh J et al (2019) Liver direct therapy corrects Fabry disease in mice. MGM 126:S17\u2013S156","journal-title":"MGM"},{"key":"721_CR48","first-page":"2","volume":"126","author":"MW Huston","year":"2019","unstructured":"Huston MW, Yasuda M, Pagant S et al (2019) Liver-targeted AAV gene therapy vectors produced by a clinical scale manufacturing process result in high, continuous therapeutic level of enzyme activity and effective substrate reduction model Fabry disease. MGM 126:2","journal-title":"MGM"},{"key":"721_CR49","first-page":"S17","volume":"126","author":"M Yoshimitsu","year":"2019","unstructured":"Yoshimitsu M, Tao K, Fan X et al (2019) Neonatal gene therapy with a lentiviral vector results in therapeutic levels of \u03b1 galactosidase A Correction in Fabry mice. MGM 126:S17\u2013S156","journal-title":"MGM"},{"key":"721_CR50","first-page":"S17","volume":"126","author":"O Saida","year":"2019","unstructured":"Saida O, Biferi MG, San Millan B et al (2019) Functional evaluation of an AAV (based vector expressing alpha\/galactosidase A for potential gene therapy. Mol Genet 126:S17\u2013S1562","journal-title":"Mol Genet"},{"key":"721_CR51","first-page":"S17","volume":"126","author":"B Kevany","year":"2019","unstructured":"Kevany B, Kerns S, Padegimas L, Miller J (2019) AAV gene therapy for treatment of Fabry disease A novel capsid with improved tropism to heart, kidney and CNS and improved GLA expression. MGM 126:S17\u2013S156","journal-title":"MGM"},{"key":"721_CR52","first-page":"S17","volume":"126","author":"JA Medin","year":"2019","unstructured":"Medin JA, Khan A, Huang J et al (2019) FACTs Fabry gene clinical trial: two-year data. MGM 126:S17\u2013S156","journal-title":"MGM"},{"issue":"21","key":"721_CR53","doi-asserted-by":"crossref","first-page":"13777","DOI":"10.1073\/pnas.222221899","volume":"99","author":"H Takahashi","year":"2002","unstructured":"Takahashi H, Hirai Y, Migita M et al (2002) Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. PNAS 99(21):13777\u201313782","journal-title":"PNAS"},{"key":"721_CR54","first-page":"12676","volume":"98","author":"SC Jung","year":"2001","unstructured":"Jung SC, Han IP, Limaye A et al (2001) Adeno-associated viral vector-mediated gene transfer results in long term enzymatic and functional correction in multiple organs of Fabry mice. PNAS 98:12676\u201312681","journal-title":"PNAS"},{"issue":"3","key":"721_CR55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","volume":"15","author":"RJ Ziegler","year":"2007","unstructured":"Ziegler RJ, Cherry M, Barbon CM et al (2007) Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther 15(3):492\u2013500","journal-title":"Mol Ther"},{"issue":"9","key":"721_CR56","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/sj.mt.6300219","volume":"15","author":"DE Sabatino","year":"2007","unstructured":"Sabatino DE, Mackenzie TC, Peranteau W et al (2007) Persistent expression og hF.IX after tolerance induction by in utero or neonatal administration of AAV-1-F. IX in haemophilia B mice. Mol Ther 15(9):1677\u20131685","journal-title":"Mol Ther"},{"key":"721_CR57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/DDDT.S36131","volume":"6","author":"APR de Garibay","year":"2012","unstructured":"de Garibay APR, Delgado D, Del Porto-Rodriguez M et al (2012) Multicomponent as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des Dev Ther 6:303\u2013310","journal-title":"Drug Des Dev Ther"},{"issue":"12","key":"721_CR58","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neuber LP, Rudnicki M et al (2018) Replacement therapy on neutralizing antidrug antibodies titters and clinical outcome in patients with Fabry. J Am Soc Nephrol 29(12):2879\u20132889","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00721-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-020-00721-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00721-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:51Z","timestamp":1777564551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/1\/221\/8326063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00721-4","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"14 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sandro Feriozzi has received honoraria for advisory boards and travel expenses from Amicus, Sanofi Genzyme, and Takeda Shire*; received fees from Amicus, Otsuka, Sanofi Genzyme, and Takeda\/Shire*. Deralynn Hughes has received travel and research grants and honoraria for speaking and advisory boards from Amicus, Genzyme, Protalix, and Shire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript is a review of previously published papers and there are no new, unpublished data. All data were reported in official journals in which it is declared that the studies have been approved by the appropriate institutional and\/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participants and\/or animals"}},{"value":"This manuscript is a review of previously published papers and there are no new, unpublished data. In all papers it was reported that the informed consent of patients was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}